The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of stroke is listed in the xact instructions for use as a known potential adverse effect associated with carotid stents and embolic protection systems.In this case, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.Based on the case information, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The treatment with medications was related to case circumstances.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was to treat a carotid artery.A xact stent was implanted without issues and worked as intended.The patient was fine and sent to the post operation room.However, two hours later, the patient became unresponsive and started showing unspecified stroke symptoms.A computed tomography scan was performed and did not reveal any bleed.Therefore, tissue plasminogen activator (tpa) medication was provided and the patient condition improved.Per the physician, the xact stent did not cause or contribute to the stroke symptoms but rather the patients clinical condition of contralateral occlusion did.There was no adverse patient sequela and no clinically significant delay.No additional information was provided.
|